Note Added in Proof
During proofreading the results of four important clinical trials became published:
Ray KK et al. Two Phase 3 Trials of Inclisiran in Patients with Elevated LDL Cholesterol. N Engl J Med 2020, doi: 10.1056/NEJMoa1912387, ORION-10 and ORION-11 (NCT03399370 and NCT03400800);
Raal FJ et al. Inclisiran for the Treatment of Heterozygous Familial Hypercholesterolemia. N Engl J Med 2020, doi: 10.1056/NEJMoa1913805, ORION-9 (NCT03397121);
Ray KK et al. Effect of Apabetalone Added to Standard Therapy on Major Adverse Cardiovascular Events in Patients With Recent Acute Coronary Syndrome and Type 2 Diabetes: A Randomized Clinical Trial. JAMA 2020, doi: 10.1001/jama.2020.3308, BETonMACE (NCT02586155).
F.P. is the recipient of a H.H. Sheikh Khalifa bin Hamad Al Thani Foundation Assistant Professorship at the Faculty of Medicine, University of Zurich.
Eur Heart J. 2020;41(40):3884-3899. © 2020 Oxford University Press
Copyright 2007 European Society of Cardiology. Published by Oxford University Press. All rights reserved.